• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CTIC

CTIC

CTI BioPharma Corp.

NASDAQHealthcareBiotechnologyUS

USD9.10

+0.01 (+0.06%)

Company Profile

CEO

Adam R. Craig

IPO Date

1997-03-21

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$9.10

Prev. Close

$9.09

Day Low

$9.09

Day High

$9.10

52W Low

$4.01

52W High

$9.10

Market Cap

$1.20B

Volume

5.56M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

35.1%

Avg Negative

4.5%

Avg Neutral

60.4%

News Feed

CTIC Stock: Over 5% Increase Pre-Market Explanation

Pulse2·8/25/2021·↑ positive

CTI BioPharma Announces Appointment of Diane Parks to Its Board of Directors

PRNewsWire·8/24/2021·↑ positive

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/5/2021·↓ negative

CTI BioPharma Reports Second Quarter 2021 Financial Results

PRNewsWire·8/5/2021·↑ positive

CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Wednesday, June 16

PRNewsWire·6/9/2021·↑ positive

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·6/1/2021·↓ negative

CTI BioPharma Reports First Quarter 2021 Financial Results

PRNewsWire·6/1/2021·↑ positive

CTI BioPharma Shares Shoot Higher as FDA Accepts Pacritinib Review Application In Bone Marrow Cancer

Benzinga·6/1/2021·↑ positive

CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis

PRNewsWire·6/1/2021·↑ positive

CTI BioPharma to Report First Quarter 2021 Financial Results on June 1, 2021

PRNewsWire·5/5/2021·↓ negative